Core Viewpoint - Rongchang Biotech (09995) has entered into an agreement with SPD Bank Yantai Branch to invest RMB 400 million of its idle funds in a wealth management product [1] Summary by Categories Company Actions - The company has agreed to purchase a wealth management product from SPD Bank Yantai Branch using RMB 400 million of its idle self-owned funds [1]

Core Viewpoint - Rongchang Biologics (09995) has announced an agreement with Pudong Development Bank Yantai Branch to invest RMB 400 million of its idle funds in a wealth management product [1] Group 1 - The company will purchase the wealth management product on November 3, 2025 [1] - The investment amount is set at RMB 400 million, indicating a strategic use of idle funds [1]

Core Viewpoint - Rongchang Bio (09995) has entered into an agreement with SPD Bank Yantai Branch to invest a total of RMB 5 billion in wealth management products, utilizing both idle self-owned funds and idle raised funds [1] Group 1 - The company will invest RMB 400 million of its idle self-owned funds in the wealth management products [1] - The company will also invest RMB 100 million of its idle raised funds in the wealth management products [1]

Group 1 - Company Rongchang Bio (09995) announced an agreement with Pudong Development Bank Yantai Branch to purchase wealth management products [1] - The company will invest a total of RMB 5 billion, consisting of RMB 4 billion of idle self-owned funds and RMB 1 billion of idle raised funds [1]

Core Viewpoint - Rongchang Biologics (09995.HK) has entered into an agreement with Pudong Development Bank Yantai Branch to invest a total of RMB 5 billion in wealth management products, utilizing both idle self-owned funds and raised funds [1] Group 1 - The company will invest RMB 4 billion of idle self-owned funds in wealth management products [1] - The company will also invest RMB 1 billion of idle raised funds in wealth management products [1]

Core Viewpoint - The company, Magmi Tech, announced on October 15, 2025, that it will continue to utilize part of its idle raised funds for cash management to improve the efficiency of fund usage while ensuring project funding needs are met [1] Group 1: Cash Management of Idle Funds - The company has set a cash management limit of no more than 100 million yuan for idle funds from the 2019 convertible bonds and 300 million yuan for the 2022 convertible bonds, with a maximum term of 12 months [1] - The company has successfully redeemed investments made with idle funds, including a total of 2 million yuan invested in structured deposits with Shanghai Pudong Development Bank, yielding a return of 97,111.11 yuan by October 9, 2025 [2] - Another 2 million yuan was invested in a different structured deposit with the same bank, yielding a return of 32,222.22 yuan by the announcement date [2] Group 2: 2019 Convertible Bonds Cash Management - The company issued a total of 655 million yuan in convertible bonds in 2019, and has utilized idle funds for cash management, achieving a total return of 872,333.33 yuan from a rolling amount of 60 million yuan over the past twelve months [4] - The cash management products included a structured deposit with a guaranteed principal and an expected annual yield of 0.7% to 2.35% [2] Group 3: 2022 Convertible Bonds Cash Management - In 2022, the company issued convertible bonds totaling 1.22 billion yuan, with cash management activities yielding a total return of 1,556,153.37 yuan from a rolling amount of 213 million yuan [4] - The cash management products included a one-year CD with an expected annual yield of 1.70% and a six-month CD with an expected yield of 1.35% [3] Group 4: Risk Management and Company Impact - The company has implemented several risk control measures for its cash management activities, including financial department evaluations and independent oversight by directors and supervisors [4] - The use of idle funds for low-risk financial products is expected to enhance fund efficiency and asset returns without affecting the cash flow for project investments [4]

Core Viewpoint - Rongchang Biologics (09995) has entered into an agreement with Pudong Development Bank Yantai Branch to invest RMB 300 million of its idle funds in a wealth management product [1] Group 1 - The company has committed to purchasing a wealth management product from Pudong Development Bank Yantai Branch [1] - The investment amount is set at RMB 300 million [1] - The agreement is scheduled to take effect on August 29, 2025 [1]